Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Genetic Tech Spn Ads (GENE)

3.9   -0.05 (-1.27%) 08-14 16:00
Open: 3.96 Pre. Close: 3.95
High: 4.0196 Low: 3.9
Volume: 457,702 Market Cap: 58M
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. The company also engages in the development of various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer name. In addition, it offers genetic testing services, including medical, animal, forensic, and plant testing.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.022 - 4.049 4.049 - 4.071
Low: 3.849 - 3.875 3.875 - 3.896
Close: 3.862 - 3.904 3.904 - 3.939

Technical analysis

as of: 2020-08-14 4:30:23 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 8.41     One year: 12.03
Support: Support1: 2.19    Support2: 1.82
Resistance: Resistance1: 7.20    Resistance2: 10.30
Pivot: 4.05
Moving Average: MA(5): 4.00     MA(20): 4.14
MA(100): 2.59     MA(250): 2.52
MACD: MACD(12,26): 0.18     Signal(9): 0.28
Stochastic oscillator: %K(14,3): 23.60     %D(3): 25.05
RSI: RSI(14): 51.52
52-week: High: 10.30  Low: 1.41  Change(%): 109.7
Average Vol(K): 3-Month: 799759  10-Days: 107607

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
GENE has closed above bottom band by 20.9%. Bollinger Bands are 59.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to GENE's normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Tue, 30 Jun 2020
Enrollment Opens for Dravet Patients in MONARCH Trial of STK-001 - Dravet Syndrome News

Tue, 26 May 2020
Dravet Patient Enrollment Begins Later This Year for MONARCH Trial - Dravet Syndrome News

Tue, 03 Dec 2019
Gene Therapies for Dravet, Other Rare Diseases Goal of StrideBio, Sarepta Partnership - Dravet Syndrome News

Tue, 23 Jul 2019
Encoded Earns $104M in Financing to Advance Potential Gene Therapy... - Dravet Syndrome News

Tue, 04 Jun 2019
Dravet Syndrome: New Mutation Found in SCN1A Gene, Case Study Says - Dravet Syndrome News

Tue, 19 Feb 2019
NGS Reveals New Mutations Linked to Epilepsy and Dravet Syndrome - Dravet Syndrome News

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ Capital Market
Sector:  Healthcare
Industry:  Diagnostics & Research
Shares Out. (M) 14
Shares Float (M) 6
% Held by Insiders 2.60
% Held by Institutions 1.99
Shares Short (K) 80
Shares Short P. Month (K) 25

Stock Financials

EPS -0.300
EPS Est This Year -1.720
EPS Est Next Year -1.490
Book Value (p.s.) 0.150
Profit Margin
Operating Margin
Return on Assets (ttm) -96.7
Return on Equity (ttm) -202.3
Qtrly Rev. Growth -96.8
Gross Profit (p.s.) -0.018
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth
Operating Cash Flow (M)
Levered Free Cash Flow (M)

Stock Valuations

PE Ratio -13.00
PEG Ratio
Price to Book value 26.00
Price to Sales
Price to Cash Flow

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.